Medical marijuana stocks have been all the rage and CARA has been lumped into that category, but the story is much deeper. Dr. Derek Chalmer, CEO of Cara Therapeutics joins Jill Malandrino at the NASDAQ MarketSite to give a complete review of the company. The company's lead program is an opiate-based program with the promise of analgesia with no narcotic side effects. CARA's main focus is obtaining approval for the first medications for 2016.

If you liked this article you might like

Trump's FDA: A Friendlier Biotech Sheriff

Mattel, Mazor, Raytheon: 'Mad Money' Lightning Round (7/10/17)

These Stocks Are Changing Directions

Watching the Dip Buyers This Morning